Immunovant, Inc. reported shareholder vote results
SEC 8-KRead source ↗
Immunovant, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in March.
Who’s trading
What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.
- Insiders0 buying, 9 selling0 purchases and 62 sales by directors and officers, last 12 monthsInsider trades
- Funds110 adding, 101 cuttingOf 43 active managers that changed their stake, 24 added; quarter to June 30, 2026Fund buyers and sellers
The Fundamentalytics view
Current signal Results well short of expectations: Reported earnings per share missed the analysts' consensus estimate by 10% in the quarter to 2026-06-30.
Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.
Highlights
How we pick theseStrengths
Nothing in Immunovant, Inc.'s latest figures clears our strength thresholds.
Things to watch
- Results due soon. Results are expected around 9 November; the share price can move sharply on the day.
- Volatile shares. Over the past year the shares showed annualised volatility of 56% and a beta of 1.4 against the S&P 500.
- Insiders selling. 9 insiders sold $17M of stock over the past 365 days and none bought (8% under pre-set trading plans).
- Heavily shorted. 19.7% of the shares available to trade are sold short (10.9 days of average volume to cover).
- Missing expectations. Earnings per share fell short of the consensus estimate in 2 of the last four quarters.
Latest results
- Earnings per share
- -$0.68 against an average estimate of -$0.61: missed by 10.5%
- Share reaction
- +1.7% in the first session after the results on August 6, 2026, against +0.5% for the S&P 500
- Next report
- November 9, 2026; average EPS estimate -$0.72
Price chart
- 1 day-2.6%
- 1 week+0.9%
- 1 month-15.5%
- This year+11.8%
- 1 year+15.1%
- 5 years+220.7%
- S&P 500 this year+11.2%
Loading chart…
Third-party market data · may be delayed
At a glance
Earnings
- Last results
- August 6, 2026
- Next results (est.)
- November 9, 2026
News & updates
Company announcements, filed results and changes that matter to shareholders.
- Shareholder vote
- Results
Immunovant, Inc. reported results
SEC 8-KRead source ↗
No model value for Immunovant, Inc. at the moment. Current status: limited reported history: available models are shown without a Buy/Hold/Sell rating. Available reported financials are shown below.
Moat
Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.
Forecasts and guidance
Next results: November 9, 2026, before the open. Analysts expect revenue of $0 and EPS of −$0.72 (range −$0.76 to −$0.70) for the quarter.
Analysts' consensus
| Fiscal year | EPS | Growth | Revenue | Growth |
|---|---|---|---|---|
| Current | −$2.84 | −15% | — | 0% |
| Next | −$2.75 | +3% | $37m | 0% |
How the EPS forecast has moved
The consensus EPS forecast for the current fiscal year is +12.9% on 90 days ago. In the last 30 days, 0 analysts raised Immunovant, Inc.'s forecast and 3 cut it.
Average of analysts' published estimates (third-party data).
View chart data
| Period | Current fiscal year | Next fiscal year |
|---|---|---|
| 90 days ago | −$2.52 | −$2.40 |
| 60 days ago | −$2.58 | −$2.50 |
| 30 days ago | −$2.84 | −$2.22 |
| 7 days ago | −$2.84 | −$2.50 |
| Now | −$2.84 | −$2.75 |
Earnings against estimates
| Quarter to | Estimate | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | −$0.61 | −$0.68 | −10.5% |
| Mar 2026 | −$0.63 | −$0.67 | −7.5% |
| Dec 2025 | −$0.69 | −$0.54 | +22.4% |
| Sept 2025 | −$0.73 | −$0.65 | +10.6% |
Adjusted EPS as companies report it, against the average analyst estimate.
Positioning
- Short interest
- 19.7% of tradable shares
- Days to cover
- 10.91 at average volume
- Short interest, 1 month
- +6% to October 15, 2026
- Held by institutions
- 55% of shares
- Held by insiders
- 56.0% of shares
- Employees
- 315 full time
Share-price performance
Market data may be delayedReturn and risk by year
| Calendar year | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 to date |
|---|---|---|---|---|---|---|
| Return | ||||||
| IMVT | −82% | +108% | +137% | −41% | +3% | +12% |
| Industry peers (median) | −35% | −57% | −18% | −28% | −5% | −27% |
| S&P 500 | +29% | −18% | +26% | +25% | +18% | +11% |
| Months that ended higher | ||||||
| IMVT | 25% | 50% | 58% | 33% | 42% | 64% |
| S&P 500 | 75% | 42% | 67% | 75% | 75% | 46% |
| Largest fall from a high during the year | ||||||
| IMVT | −86% | −62% | −28% | −46% | −47% | −41% |
| S&P 500 | −5% | −25% | −10% | −8% | −19% | −9% |
Worst fall since June 21, 2019: 94% from November 17, 2020 to June 16, 2022. Getting back needed a 1460% gain, and the shares have not yet recovered.
Price behaviour
- 52-week range
- $22.02 – $44.96
- From 52-week high
- −36.8%
- vs 50-day average
- −17.0%
- vs 200-day average
- −11.4%
- Volatility (1 year)
- 56%
- Beta vs S&P 500
- 1.36
Share price after results
- Next day
- 6 up, 6 down typical move ±6.7%
- After a week
- 8 up, 4 down typical move ±9.2%
- After a month
- 7 up, 5 down typical move ±12.7%
| Results released | Next day | S&P 500 next day | 5 days | 21 days |
|---|---|---|---|---|
| August 6, 2026 | +1.7% | +0.5% | +6.5% | −0.1% |
| May 20, 2026 | +29.8% | +1.2% | +27.4% | +44.9% |
| February 6, 2026 | +14.3% | +2.4% | +7.0% | +6.9% |
| November 10, 2025 | −2.0% | +1.8% | +4.1% | +0.9% |
| August 11, 2025 | −1.6% | +0.9% | −1.3% | +4.8% |
| May 29, 2025 | +5.3% | +0.3% | +13.6% | +13.5% |
| February 6, 2025 | −9.3% | −0.6% | −11.8% | −9.8% |
| November 7, 2024 | −2.5% | +1.2% | −10.7% | −8.7% |
| August 6, 2024 | +1.0% | +0.2% | +11.5% | +25.9% |
| May 29, 2024 | −7.1% | −1.4% | −9.9% | −7.1% |
| February 12, 2024 | +4.0% | −1.4% | +5.6% | −10.4% |
| November 9, 2023 | −2.3% | +0.8% | +1.0% | +19.1% |
Fundamentals
Who owns it
Funds buying and selling- Reported value
- $4.3B
- Institutions reporting
- 224
- Shares held vs prior quarter
- ▼ 0.9%
- Positions opened / closed
- 36 / 22
| Manager | Value | Shares | Share of 13F value | Shares QoQ |
|---|---|---|---|---|
| FMR LLC | $624M | 16.2M | 14.7% | ▼ 4.5% |
| Deep Track Capital, LP | $360M | 9.3M | 8.5% | ▼ 19.0% |
| Blackrock, Inc. | $277M | 7.2M | 6.5% | ▲ 9.2% |
| Farallon Capital Management, L.L.C. | $224M | 5.8M | 5.3% | ▲ 275.5% |
| Baker Bros. Advisors LP | $209M | 5.4M | 4.9% | ▼ 0.4% |
| State Street Corp | $178M | 4.6M | 4.2% | ▲ 1.7% |
| Morgan Stanley | $175M | 4.5M | 4.1% | ▲ 17.0% |
| Tcg Crossover Management, LLC | $172M | 4.5M | 4.0% | 0.0% |
| Vanguard Portfolio Management LLC | $151M | 3.9M | 3.5% | ▲ 5.5% |
| Vanguard Capital Management LLC | $140M | 3.6M | 3.3% | ▲ 0.5% |
| Jennison Associates LLC | $128M | 3.3M | 3.0% | ▲ 3.6% |
| RTW Investments, LP | $122M | 3.2M | 2.9% | 0.0% |
From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Immunovant, Inc.'s complete shareholder register. Values are as reported by the filers ; 1 inconsistently scaled filing rows were excluded.
Insider trading activity
Full insider history and chart Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $16.5M 62 trades by 9 insiders · 8% under pre-set plans
Net ▼ $16.5M net selling
| Insider | Date | Trade | Shares | Price | Value |
|---|---|---|---|---|---|
| Girao Tiago Chief Financial Officer | October 28, 2026 | Sell | 6,606 | $28.50 | $188,271 |
| Stout Jay S Chief Technology Officer | October 21, 2026 | Sell | 2,595 | $28.94 | $75,099 |
| Gloria Melanie Chief Operating Officer | October 7, 2026 | Sell | 2,241 | $32.06 | $71,846 |
| Van Tuyl Christopher Chief Legal Officer | October 7, 2026 | Sell | 1,327 | $32.06 | $42,544 |
| Stout Jay S Chief Technology Officer | October 7, 2026 | Sell | 1,596 | $32.06 | $51,168 |
| Stout Jay S Chief Technology Officer | October 7, 2026 | Sell | 2,213 | $32.06 | $70,949 |
| Venker Eric Chief Executive Officer | October 2, 2026 | Sell | 3,506 | $34.11 | $119,590 |
| Van Tuyl Christopher Chief Legal Officer | September 23, 2026 | Sell | 2,846 | $36.36 | $103,481 |
| Pande Atul Director | August 28, 2026 | Sell pre-set plan | 1,500 | $43.27 | $64,905 |
| Gloria Melanie Chief Operating Officer | August 20, 2026 | Sell | 3,056 | $44.16 | $134,953 |
| Pande Atul Director | July 24, 2026 | Sell pre-set plan | 1,500 | $39.80 | $59,700 |
| Stout Jay S Chief Technology Officer | July 23, 2026 | Sell | 2,857 | $38.69 | $110,537 |
From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.
Earnings dates and SEC filings
Results announcements
Next expected around November 9, 2026 estimated from the company's past filing pattern, not announced
- August 6, 2026
- May 20, 2026
- February 6, 2026
- November 10, 2025
- August 11, 2025
- May 29, 2025
Recent SEC filings
- 8-K Current report
- 10-Q Quarterly report
- 8-K Current report
- DEF 14A Proxy statement
- 10-K Annual report
- 8-K Current report
- 10-Q Quarterly report
- 8-K Current report
Data status
| Data | Last updated | Source |
|---|---|---|
| Share price | Exchange closing prices | |
| News and updates | Company releases and SEC 8-K filings | |
| Analyst estimates | Aggregated analyst estimates | |
| Valuation and scores | Our models, from the filed figures |
Immunovant, Inc. in brief
- What does Immunovant, Inc. do?
- Immunovant, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in March.
- What is Immunovant, Inc.'s stock ticker?
- Immunovant, Inc. trades under the ticker IMVT on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
- Who are Immunovant, Inc.'s largest institutional shareholders?
- By value reported in 13F filings for June 30, 2026, the largest reported holders are FMR LLC, Deep Track Capital, LP and Blackrock, Inc. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
- Are insiders buying or selling Immunovant, Inc. stock?
- Over the last 12 months, Immunovant, Inc.'s directors and officers reported 0 open-market purchases and 62 sales on Form 4. The insider trading page charts every trade.
- When is Immunovant, Inc.'s next earnings date?
- Around November 9, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Immunovant, Inc. announces its own schedule.
Follow research on Immunovant, Inc.
New research on the companies we cover arrives in the weekly email. Free, one email a week.